Parecoxib inhibits apoptosis in acute myocardial infarction due to permanent coronary ligation but not due to ischemia-reperfusion

J Cardiovasc Pharmacol. 2009 Jun;53(6):495-8. doi: 10.1097/FJC.0b013e3181a7b5b6.

Abstract

Purpose: Myocardial ischemia induces cyclooxygenase 2 (COX-2) expression. We evaluated the effects of parecoxib, a COX-2 inhibitor, in 2 different mouse models of myocardial ischemia: permanent left coronary artery ligation (PI) and transient ligation (30 minutes ischemia) followed by reperfusion (I/R).

Methods: Forty adult male Institute of Cancer Research mice underwent PI (n = 24) or I/R (n = 16), followed by randomization to parecoxib (0.75 mg/kg intraperitoneal daily) or normal saline for 7 days.

Results: Parecoxib significantly reduced apoptosis [0.8% vs. 3.4% (saline), P < 0.001] and 7-day mortality [0% vs. 57% (saline), P = 0.040] in the PI group but showed no benefit in the I/R group. Parecoxib-treated mice also exhibited greater fractional shortening in the PI group [22% vs. 14% (saline), P = 0.045) but not in the I/R group. Parecoxib did not affect infarct size in either group.

Conclusions: COX-2 may play a pivotal role in mediating apoptosis in the ischemic peri-infarct myocardium that is not reperfused after infarct.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Disease
  • Animals
  • Apoptosis / drug effects*
  • Coronary Stenosis / complications*
  • Coronary Vessels
  • Cyclooxygenase 2 Inhibitors / pharmacology*
  • Cyclooxygenase 2 Inhibitors / therapeutic use
  • Disease Models, Animal
  • Echocardiography
  • Injections, Intraperitoneal
  • Isoxazoles / pharmacology*
  • Isoxazoles / therapeutic use
  • Ligation
  • Male
  • Mice
  • Myocardial Infarction / drug therapy*
  • Myocardial Infarction / etiology
  • Myocardial Infarction / pathology
  • Myocardial Reperfusion Injury / complications
  • Myocardial Reperfusion Injury / drug therapy*
  • Myocardial Reperfusion Injury / pathology
  • Myocardium / pathology
  • Ventricular Remodeling / drug effects

Substances

  • Cyclooxygenase 2 Inhibitors
  • Isoxazoles
  • parecoxib